Abstract
The common denominator between the commercial companies, wanting to optimise profits from existing and novel pharmaceuticals, and the national regulatory licensing authorities, is that both want to make safe, new drugs available to the patient population. For example, the EEC Rules which govern medicaments (1) state that the primary purpose of the comunity rules relating to the medicinal products is to safeguard public health whilst at the same time ensuring that the development of the pharmaceutical industry and trade in medicinal products will not be hindered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
